Boston, Massachusetts, USA, April 6, 2026
Breakthrough Results in Rare Pediatric Epilepsy
In a major advancement for precision neuroscience and rare disease therapeutics, Praxis Precision Medicines has announced positive topline results from the EMBRAVE Part A Phase 1/2 clinical trial evaluating elsunersen (PRAX-222) in children with SCN2A early-onset developmental and epileptic encephalopathy (DEE). The study demonstrated a 77% placebo-adjusted reduction in seizure frequency, a statistically significant outcome (p=0.015), highlighting the therapy’s potential to address one of the most severe forms of genetic epilepsy. Notably, 71% of treated patients achieved more than 50% seizure reduction, and 57% experienced at least one 28-day seizure-free period, indicating substantial clinical benefit in a population with limited treatment options. Beyond seizure control, 100% of patients receiving elsunersen showed improvements in neurological functions, including sleep, motor skills, muscle tone, and attention, reinforcing its potential as a disease-modifying therapy rather than a symptomatic treatment.
Sustained Efficacy and Strong Safety Profile
The trial results further demonstrated durable and sustained efficacy, with benefits maintained in the open-label extension (OLE) for up to one year, a critical factor in evaluating long-term therapeutic value in chronic neurological conditions. Importantly, elsunersen exhibited a favorable safety and tolerability profile, with no treatment-related serious adverse events (SAEs), no discontinuations, and no evidence of neuroinflammation, a key concern in central nervous system therapies. Most treatment-emergent adverse events (TEAEs) were reported as mild to moderate, supporting the drug’s suitability for pediatric use.
The therapy works as an antisense oligonucleotide (ASO) designed to selectively reduce SCN2A gene expression, directly targeting the underlying genetic cause of the disease. Preclinical and clinical findings consistently demonstrate dose-dependent seizure reduction, improved behavioral outcomes, and enhanced survival, positioning elsunersen as a potential first-in-class therapeutic for SCN2A-DEE.
Advertisement
Advancing Toward Pivotal Development
Following these promising results, Praxis is progressing with its pivotal EMBRAVE3 study, aiming to further validate efficacy and safety in a larger patient population and support potential regulatory approval pathways. The EMBRAVE Part A trial enrolled pediatric patients aged 2 to 12 years, utilizing a randomized, placebo-controlled design with dose escalation to optimize treatment outcomes.
Regulatory momentum is also strong, with elsunersen receiving Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) from the U.S. FDA, as well as PRIME designation from the European Medicines Agency, reflecting its importance in addressing a significant unmet medical need. The therapy is being developed in collaboration with Ionis Pharmaceuticals, leveraging advanced antisense technology platforms to target neurological disorders at the genetic level.
Transforming the Future of Precision Neurology
The success of elsunersen underscores the growing impact of genetic-targeted therapies in neurology, particularly for rare and severe pediatric disorders. SCN2A-DEE is characterized by early-onset seizures, developmental delays, and significant neurological impairment, often leading to lifelong disability and reduced quality of life. Current treatment options remain limited and largely ineffective in modifying disease progression. By directly addressing the root genetic driver, elsunersen represents a next-generation therapeutic approach with the potential to transform disease management and improve long-term outcomes.
As the field of precision medicine continues to evolve, therapies like elsunersen highlight the importance of targeted, mechanism-driven drug development in unlocking new possibilities for patients with previously untreatable conditions. The upcoming clinical milestones will be closely watched as Praxis continues to advance its innovative CNS pipeline and redefine standards of care in neurological diseases.
Source: Praxis Precision Medicines press release
